Daré Bioscience, Inc. announced on September 24, 2025, that it has entered into an agreement with the Gates Foundation to receive up to approximately $499,000. This funding is designated to support third-party research projects focused on preeclampsia.
Under this engagement, Daré will provide strategic mentorship, technical guidance, and tailored project management support to Grand Challenges grantee organizations worldwide. These organizations are conducting preclinical research aimed at the prevention, diagnosis, and treatment of preeclampsia.
Preeclampsia is a severe pregnancy complication and a leading cause of maternal and infant illness and death globally, with no FDA-approved treatments currently available. This initiative allows Daré to contribute its expertise to a critical unmet need in women's health and gain valuable insights into this area.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.